海西新药(02637)以上限定价 香港公开发售获3165.1倍认购

Core Viewpoint - HaiXi New Drug (02637) has successfully completed its global offering of 11.5 million H-shares, raising approximately HKD 940 million with a final offering price of HKD 86.40 per share [1] Summary by Category Offering Details - The global offering consisted of 10% allocated for public sale in Hong Kong and 90% for international sale [1] - The offering was oversubscribed, with the Hong Kong public offering receiving 3165.1 times subscription and the international offering receiving 6.3 times subscription [1] Trading Information - The H-shares are expected to commence trading on the Hong Kong Stock Exchange on October 20, 2025, at 9:00 AM [1]